Takeda & Shattuck Labs Announce Research Collaboration to Explore Agonist Redirected Checkpoint Fusion Proteins in Immuno-Onc...
2017年8月10日 - 10:00PM
ビジネスワイヤ(英語)
Takeda Pharmaceutical Company Limited (TSE: 4502) and Shattuck
Labs, Inc. announced today that they have entered into a research
collaboration to explore and develop checkpoint fusion proteins
that have the potential to become highly differentiated,
next-generation immunotherapies. Under the terms of the
collaboration agreement, Takeda will hold options for exclusive
global development and commercialization rights for up to four
molecules resulting from the collaboration.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170810005035/en/
Shattuck Lab’s Agonist Redirected Checkpoint (ARC)™ platform
combines two binding domains to create fusion proteins that
potentially restore and enhance immune system function in a single
construct. The ARC molecules block checkpoint molecules while
simultaneously stimulating TNF superfamily co-stimulatory receptors
on T-cells and innate cells, which are targets controlling the
immune system and often dysregulated in cancers, thereby enabling
combination immunotherapy with a single product.
"Shattuck Labs has pioneered the unique ARC platform, and we are
excited about the opportunity this collaboration presents to
develop groundbreaking, next-generation immuno-oncology
treatments," said Christopher Arendt, Ph.D., Head, Oncology DDU
& Immunology Unit, Takeda. "Research partnerships are a key
aspect of our continued dedication to oncology innovation, and this
collaboration will bring us closer to our goal of discovering,
developing and delivering breakthrough oncology therapies.”
The collaboration will include two pre-clinical and four
discovery stage programs. Takeda will provide funding for
pre-clinical and clinical development and will have the option to
take an exclusive license to further develop and commercialize up
to four ARC molecules resulting from the collaboration. Additional
terms of the collaboration are not disclosed.
“Takeda shares our passion and mission to develop and advance
novel therapies in oncology, with the goal of achieving better
clinical outcomes in patients,” said Josiah Hornblower, Chairman
and CEO of Shattuck Labs. "We are very excited to work with Takeda,
a proven leader in oncology, to continue to validate the ARC
technology.”
Takeda signed the collaboration agreement through its
wholly-owned subsidiary, Millennium Pharmaceuticals, Inc.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing
better health and a brighter future to patients by translating
science into life-changing medicines. Takeda focuses its R&D
efforts on oncology, gastroenterology and central nervous system
therapeutic areas plus vaccines. Takeda conducts R&D both
internally and with partners to stay at the leading edge of
innovation. New innovative products, especially in oncology and
gastroenterology, as well as Takeda’s presence in Emerging Markets,
are currently fueling the growth of Takeda. More than 30,000 Takeda
employees are committed to improving quality of life for patients,
working with Takeda’s partners in health care in more than 70
countries. For more information, visit www.takeda.com/news.
About Shattuck Labs
Headquartered in Austin, Texas, Shattuck Labs, Inc. is a
biopharmaceutical company committed to developing biologic
medicines for oncology and inflammatory disease. Shattuck Labs
developed the Agonist Redirected Checkpoint (ARC) platform to
enable immuno-oncology therapeutics capable of simultaneously
blocking immune checkpoints and stimulating TNF superfamily
receptors. Shattuck Lab’s state-of-the-art research and development
organization is currently advancing multiple lead products toward
clinical trials.
Takeda’s Forward-Looking Statements
This press release contains “forward-looking statements.”
Forward-looking statements include all statements other than
statements of historical fact, including plans, strategies and
expectations for the future. Statements made in the future tense
and words such as “anticipate,” “expect,” “project,” “continue,”
“believe,” “plan,” “estimate,” “pro forma,” “intend,” “potential,”
“target,” “forecast,” “guidance,” “outlook,” “seek,” “assume,”
“will,” “may,” “should,” and similar expressions are intended to
qualify as forward-looking statements. Forward-looking statements
are based on estimates and assumptions made by management that are
believed to be reasonable, though they are inherently uncertain and
difficult to predict. Investors and security holders are cautioned
not to place undue reliance on these forward-looking
statements.
Forward-looking statements involve risks and uncertainties that
could cause actual results or experience to differ materially from
those expressed or implied by the forward-looking statements. Some
of these risks and uncertainties include, but are not limited to:
applicable laws and regulations; the success or failure of product
development programs; actions of regulatory authorities and the
timing thereof; and claims or concerns regarding the safety or
efficacy of marketed products or product candidates in
development.
The forward-looking statements contained in this press release
speak only as of the date of this press release, and neither
Shattuck nor Takeda undertakes any obligation to revise or update
any forward-looking statements to reflect new information, future
events or circumstances after the date of the forward-looking
statement. If one or more of these statements is updated or
corrected, investors and others should not conclude that additional
updates or corrections will be made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170810005035/en/
Takeda Contact:Kelly Schlemm –
USAkelly.schlemm@takeda.com+1-617-551-8865orShattuck
Contact:Josiah Hornblowerjhornblower@shattucklabs.com